



Microbiome-Based Interventions in Cancer Immunotherapy

Guest Editor:

Dr. Saman Maleki Vareki

1. Department of Pathology and Laboratory Medicine, University of Western Ontario, London, ON N6A 3K7, Canada
2. London Regional Cancer Program, Lawson Health Research Institute, London, ON N6A 5W9, Canada

Deadline for manuscript submissions:

closed (30 September 2023)

Message from the Guest Editor

This Special Issue aims to gather novel data or perspectives in the area of oncomicrobiome and how microbiome-based strategies can be used to 1) select potential responders to immunotherapy, 2) modulate patients' response to these drugs, and 3) prevent toxicity in patients receiving immunotherapy.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

Role of microbiome in systemic and local cancer treatments;

The effect of the gut and tumor microbiome on response to immunotherapy with checkpoint inhibitors or adoptive cell therapy;

The role of microbiome on inducing or preventing immune-related toxicities from immunotherapy;

Mechanisms of immune modulation by gut microbiome or their products;

Microbiome-based biomarker strategies for patients receiving cancer immunotherapy;

Microbiome-based combination therapies in the area of cancer immunotherapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)